News
Grogan named Biogen research chief as reset continues
Chris Viehbacher's efforts to reinvigorate Biogen are continuing to …
19814 items found
R&D
The importance of collaboration in tackling the ethical concerns of cell and gene therapy
Cell and gene therapies (CGT) offer immense potential for healthcare …
Digital
Sponsored
Biopharma’s rapid transition to omnichannel marketing
The COVID-19 pandemic accelerated a change that was already underway …
News
Deal allows UK to rejoin EU's Horizon R&D funding scheme
After years of Brexit-related wrangling, the UK is poised to rejoin …
News
Moderna, Pfizer say COVID jabs work against BA.2.86
Moderna and Pfizer have both said that updated versions of their …
Sales & Marketing
Sponsored
Improving access to brand planning tools through modular offerings
Daniel Kohlstaedt, managing director and founder of PurpleLeaf …
News
J&J pulls out of Idorsia deal for hypertension drug
Idorsia has lost Johnson & Johnson's Janssen Biotech unit as the …
News
FDA blocks new use for AstraZeneca's Ultomiris
AstraZeneca has been successful at rolling out its long-acting …
News
Novartis loses commercial chief as Tschudin heads for exit
Marie-France Tschudin is stepping down as Novartis' chief commercial …
News
FDA starts review of Roche's PNH drug crovalimab
Roche could be just months away from FDA approval of its …
News
Biofourmis quietly parts company with CEO Rajput
It has emerged that digital health company Biofourmis is in need of a …
Sales & Marketing
Why pharmacies are turning to route optimisation
If the pandemic taught pharmaceutical suppliers anything, it’s the …
Market Access
Metrics for the UK’s VPAG: A work in progress
Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines pricing and access.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Patients
Deep Dive: Patients & Partnerships 2024
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
From neurosurgery to focused ultrasound: Not if, but when
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Welcome to the Molecular Glue Drug Development Summit!
The Molecular Glue Drug Development Summit is back in January, 2025!
R&D
Partner Content
Welcome to the 6th RNAi-Based Therapeutics Summit!
RNAi-Based Therapeutics Returns!
